BioAge Labs, Inc. (NASDAQ:BIOA) Given Consensus Recommendation of “Moderate Buy” by Brokerages

BioAge Labs, Inc. (NASDAQ:BIOA) has received an average recommendation of “Moderate Buy” from the five brokerages that are currently covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell recommendation and four have given a buy recommendation to the company. The average 12-month target price among brokerages that have issued a report on the stock in the last year is $46.25.

A number of research analysts have issued reports on the company. Morgan Stanley set a $23.00 target price on BioAge Labs in a research note on Wednesday, February 4th. Piper Sandler assumed coverage on BioAge Labs in a research note on Tuesday, January 27th. They issued an “overweight” rating for the company. Needham & Company LLC assumed coverage on BioAge Labs in a research note on Friday, March 27th. They issued a “buy” rating and a $50.00 target price for the company. Oppenheimer assumed coverage on BioAge Labs in a research note on Wednesday, February 25th. They issued an “outperform” rating and a $60.00 target price for the company. Finally, Wall Street Zen raised BioAge Labs from a “sell” rating to a “hold” rating in a research note on Tuesday, February 3rd.

BioAge Labs Trading Up 2.4%

NASDAQ:BIOA opened at $18.04 on Thursday. BioAge Labs has a 1 year low of $2.88 and a 1 year high of $24.00. The stock has a market cap of $800.62 million, a price-to-earnings ratio of -8.05 and a beta of 1.80. The stock has a 50-day moving average price of $19.54 and a two-hundred day moving average price of $13.72.

BioAge Labs (NASDAQ:BIOA) last posted its earnings results on Tuesday, March 24th. The company reported ($0.72) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.83) by $0.11. BioAge Labs had a negative return on equity of 27.86% and a negative net margin of 896.11%.The firm had revenue of $3.08 million during the quarter.

Insider Transactions at BioAge Labs

In other news, insider Paul D. Rubin sold 7,433 shares of the company’s stock in a transaction dated Monday, February 2nd. The stock was sold at an average price of $18.75, for a total transaction of $139,368.75. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CFO Dov A. Md Goldstein sold 27,000 shares of the company’s stock in a transaction dated Tuesday, January 13th. The stock was sold at an average price of $19.70, for a total value of $531,900.00. Following the transaction, the chief financial officer directly owned 22,408 shares of the company’s stock, valued at $441,437.60. This represents a 54.65% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 267,540 shares of company stock valued at $4,895,168 over the last three months. Company insiders own 20.82% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the company. CWM LLC boosted its position in shares of BioAge Labs by 39.9% during the fourth quarter. CWM LLC now owns 3,693 shares of the company’s stock worth $49,000 after buying an additional 1,053 shares during the period. Price T Rowe Associates Inc. MD boosted its position in shares of BioAge Labs by 24.5% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 14,808 shares of the company’s stock worth $196,000 after buying an additional 2,917 shares during the period. Barclays PLC boosted its position in shares of BioAge Labs by 9.3% during the fourth quarter. Barclays PLC now owns 37,780 shares of the company’s stock worth $500,000 after buying an additional 3,222 shares during the period. Bank of America Corp DE boosted its position in shares of BioAge Labs by 46.3% during the third quarter. Bank of America Corp DE now owns 11,119 shares of the company’s stock worth $65,000 after buying an additional 3,517 shares during the period. Finally, Vontobel Holding Ltd. boosted its position in shares of BioAge Labs by 36.4% during the third quarter. Vontobel Holding Ltd. now owns 15,000 shares of the company’s stock worth $88,000 after buying an additional 4,000 shares during the period.

BioAge Labs Company Profile

BioAge Labs (NASDAQ: BIOA) is a clinical-stage biotechnology company focused on discovering and developing therapies that address age-associated diseases. The company leverages its proprietary analytics platform to mine large-scale human biological data for insights into the molecular mechanisms of aging. By targeting fundamental aging pathways, BioAge aims to create interventions that extend healthspan and treat conditions that disproportionately affect older populations.

At the core of BioAge’s operations is its integrated drug discovery platform, which combines human omics datasets, machine learning algorithms and experimental validation to identify novel drug targets.